Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
Vladonix is an oral thymus bioregulator containing peptide complex A-6. One clinical study (n=42) reported T-cell normalization in 78% of subjects. Evidence is limited to a single Russian research group, but the oral format makes it one of the most accessible thymic peptides available.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Vladonix is an oral capsule. No vials, no bacteriostatic water, no syringes. Each capsule contains 10 mg of peptide complex A-6 with a total capsule weight around 215 mg including excipients. The standard community protocol is 2 capsules (20 mg) daily with breakfast for 30 days. That burns through 60 capsules per course. A 60-cap pack runs $130 to $156 depending on the distributor. If you're running the upper range of the NPCRIZ protocol (2 caps twice daily, 40 mg/day), you'll need 120 capsules per course. Take capsules with food. GI discomfort in the first few days is the most common complaint, and it almost always traces back to empty-stomach dosing. The thing most beginners miss: you won't feel anything during the 30-day course. Community members consistently report that benefits (fewer colds, improved energy) show up 4 to 12 weeks after stopping. Evaluate a course by what happens in the months following, not during.
Dosing based on Khavinson Institute protocol — 7 published references.View all sources →
Cross-check your Vladonix reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Vladonix is an oral thymus bioregulator containing peptide complex A-6. One clinical study (n=42) reported T-cell normalization in 78% of subjects. Evidence is limited to a single Russian research group, but the oral format makes it one of the most accessible thymic peptides available.